Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products
See the rest here:
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 9:30 a.m. ET in New York, NY.
Read more from the original source:
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference
- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors -
Continued here:
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Company acquired all assets for the synergistic CNSide cerebrospinal fluid diagnostic portfolio
See the original post here:
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the Bank of America Securities 2024 Health Care Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Tuesday, May 14, 2024 at 4:20 p.m. PT in Las Vegas.
Read the original here:
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
JERSEY CITY, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the first quarter ended March 31, 2024.
Here is the original post:
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
$398 million in first quarter global net product sales
Read more:
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m. ET).
See more here:
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, announced that it has initiated its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants – see Neurocrine press announcement here.
See the article here:
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults